November 13, 2013Expert Review of Cardiovascular Therapy
Investigational drugs targeting cardiac fibrosis
Key result
Therapeutic candidates including renin-angiotensin system inhibitors, inflammation modulators, and TGF-β pathway inhibitors show promise for the regression of cardiac fibrosis.
Population
Patients with cardiovascular diseases including heart failure and hypertension
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports fibrosis-targeted research; leaves open prospective trials before clinical adoption.
Structured PICO
P
Population
Patients with cardiovascular diseases including heart failure and hypertension
I
Intervention
Therapies targeting cardiac fibrosis (including renin-angiotensin system inhibitors, inflammation modulators, TGF-β pathway inhibitors, cell therapies, and genetic interventions)
Cardiac fibrosis is increasingly recognized as a reversible process, with both established drugs like RAS inhibitors and novel therapies showing promise for its regression.
Cite This Study
Roubille et al. (2013) conducted a review in Cardiac fibrosis. Investigational drugs targeting cardiac fibrosis was evaluated. Therapeutic candidates including renin-angiotensin system inhibitors, inflammation modulators, and TGF-β pathway inhibitors show promise for the regression of cardiac fibrosis.